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Pharmacokinetic interaction after oral coadministration of clarithromycin and the 
tyrosine kinase inhibitor lapatinib in rats 
Abstract 
Lapatinib is a tyrosine kinase inhibitor used to treat patients with locally advanced or metastatic breast 
cancer exhibiting overexpression of the human epidermal growth factor receptor 2 (HER2 receptor, 
ErbB2). Preclinical and clinical studies suggest that lapatinib is mainly metabolized by CYP3A4, therefore 
the study in an animal model was designed to investigate the pharmacokinetic interaction of lapatinib and 
clarithromycin, a well-known CYP3A4 inhibitor. The rats were subjected to one of the two study groups: 
lapatinib + clarithromycin (ILap+Clar; n = 6), and lapatinib + placebo (IILap; n = 6). The animals were 
treated with lapatinib in the oral single dose of 100 mg/kg. The antibiotic was administered orally at a 
dose of 25 mg/kg. Blood sampling was performed until 30 hours after dosing for pharmacokinetic 
assays. Plasma concentrations of lapatinib were measured by liquid chromatography-mass spectrometry. 
The comparison of lapatinib maximum concentration and area under the concentration-time curve in the 
ILap+Clar with the control group IILap gave the ratios of 1.38 (90% confidence interval (CI)) (1.14; 1.68) 
and 1.16 (0.75; 1.79), respectively. A statistically significant difference between analyzed groups was 
revealed only for maximum concentration (p = 0.0107). Single oral administration of clarithromycin 
significantly increased the concentration of lapatinib in rats, therefore caution should be taken during 
concomitant treatment with this macrolide and the tyrosine kinase inhibitor in patients. 
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Tyrosine kinase inhibitors (TKIs) such as ima-
tinib, sunitinib, axitinib, and lapatinib are drugs tar-
geted at specific signaling pathways and cellular
receptors which play a key role in oncogenesis (1,
2). Lapatinib (TyverbÆ) is used in combination with
capecitabine, trastuzumab or an aromatase inhibitor
to treat patients with locally advanced or metastatic
breast cancer exhibiting overexpression of the tyro-
sine-protein kinase receptor (HER2) (3). Breast can-
cer is the most common malignant tumor diagnosed
in women both in Europe and in the United States.
In 2012, over 1.67 million cases of breast cancers
were diagnosed. The breast cancer classified in the
second place the most frequent reasons of death
among women (4). Lapatinib is intensively metabo-
lized into various oxidized metabolites mainly by
CYP3A4 and CYP3A5, with a minimal share of
CYP2C19 and CYP2C8. Due to the fact that lapa-
tinib is mostly metabolized by CYP3A4 and this
isoenzyme is responsible for the biotransformation
of more than a half of drugs metabolized by the
cytochrome P450 enzyme system, there is a high
risk of drug-drug interactions (DDIs). In conse-
quence of DDIs, the efficacy of the anticancer thera-
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Abstract: Lapatinib is a tyrosine kinase inhibitor used to treat patients with locally advanced or metastatic
breast cancer exhibiting overexpression of the human epidermal growth factor receptor 2 (HER2 receptor,
ErbB2). Preclinical and clinical studies suggest that lapatinib is mainly metabolized by CYP3A4, therefore the
study in an animal model was designed to investigate the pharmacokinetic interaction of lapatinib and clar-
ithromycin, a well-known CYP3A4 inhibitor. The rats were subjected to one of the two study groups: lapatinib
+ clarithromycin (ILap+Clar; n = 6), and lapatinib + placebo (IILap; n = 6). The animals were treated with lapatinib
in the oral single dose of 100 mg/kg. The antibiotic was administered orally at a dose of 25 mg/kg. Blood sam-
pling was performed until 30 hours after dosing for pharmacokinetic assays. Plasma concentrations of lapatinib
were measured by liquid chromatography-mass spectrometry. The comparison of lapatinib maximum concen-
tration and area under the concentration-time curve in the ILap+Clar with the control group IILap gave the ratios of
1.38 (90% confidence interval (CI)) (1.14; 1.68) and 1.16 (0.75; 1.79), respectively. A statistically significant
difference between analyzed groups was revealed only for maximum concentration (p = 0.0107). Single oral
administration of clarithromycin significantly increased the concentration of lapatinib in rats, therefore caution
should be taken during concomitant treatment with this macrolide and the tyrosine kinase inhibitor in patients.
Keywords: lapatinib, clarithromycin, pharmacokinetics, drug-drug interaction, rats
645
* Corresponding author: e-mail: anialuc.farm@gmail.com
646 AGNIESZKA KARBOWNIK et al.
py may be reduced and the complications of the lap-
atinib therapy may be intensified (1, 2). Apart from
that, lapatinib is a P-glycoprotein (P-gp) substrate
and inhibitor. The inhibitory activity of P-gp may
increase the concentration of drugs which are P-gp
substrates (5). The risk of adverse reactions to lapa-
tinib increases significantly when the drug is applied
in combination with CYP3A4 inhibitors, like clar-
ithromycin, a broadly used macrolide antibiotic.
Macrolide antibiotics were conventionally divided
into 3 groups according to the interaction potential
and the degree of interaction with liver enzymes.
The first group is characterized by the strongest
capacity to inhibit CYP3A4 activity. It includes
erythromycin, which exhibits interactions with:
sufentanil, clozapine, cyclosporine, digoxin, felodi-
pine, alprazolam, and lovastatin. The second group,
which is characterized by lower affinity to CYP3A4,
includes clarithromycin and roxithromycin. The
third group includes the macrolides which in prac-
tice have no effect on the activity of liver enzymes,
e.g. azithromycin (6, 7). Clarithromycin exhibits
clinically significant interactions with statins (e.g.
atorvastatin, lovastatin, simvastatin) (8-10), antidia-
betic drugs (e.g. evogliptin) (11), benzodiazepines
(e.g. midazolam) (12), immunosuppressants (e.g.
tacrolimus (13), everolimus) (14).
Clarithromycin is commonly used in upper res-
piratory tract infections (e.g., tonsillitis, pharyngitis,
rhinosinusitis, otitis media), lower respiratory tract
infections (e.g., bronchitis, pneumonia) as well as
skin and soft tissue infections. The antibiotic is also
applied in combination with omeprazole and amox-
icillin to patients with duodenal ulcers and con-
firmed H. pylori infections. Apart from that, clar-
ithromycin is a drug whose new mechanisms of
action are still being investigated. Therefore, indica-
tions for its use may be broadened in the future. In
vitro clarithromycin and thalidomide have a syner-
gistic effect and they decrease the secretion of tumor
necrosis factor-α and interleukin-6. They inhibit the
proliferation of myeloma cells (15). Moreover, clar-
ithromycin is a negative allosteric modulator of
GABAA receptors, which might be significant in
the treatment of e.g. hypersomnia (16). It is also
applied in combination with naproxen and
oseltamivir to elderly patients hospitalized due to
the severe course of influenza with pneumonia (17).
Clarithromycin is a competitive inhibitor of organic
anion-transporting polypeptides (OATP) and one of
the best-known CYP3A4 inhibitors, which causes a
wide range of clinically significant interactions con-
firmed in vivo. This antibiotic is also a P-gp sub-
strate and a strong competitive inhibitor. 
Therefore, its concentration and the resulting
CYP3A4 inhibitory activity may be higher when it
is simultaneously applied with lapatinib, which is
also a P-gp inhibitor (18-22). It is very likely that
clarithromycin will be applied to oncological
patients treated with lapatinib. The confirmation or
exclusion of pharmacokinetic interaction between
these drugs provides information about the need to
modify the dose of lapatinib.
The aim of the experiment was to assess the
influence of clarithromycin on the pharmacokinetics
of lapatinib in rats. Rats are very often used in the
research model for understanding human diseases
and drug interactions (including tyrosine kinase
inhibitors), but interspecies differences in terms of
CYP3A activity suggest that caution should be
applied when extrapolating metabolism data from
animal models to humans (23-26). 
EXPERIMENTAL
Reagents
Lapatinib (CAS number 231277-92-9),
methanol, acetonitrile, formic acid, ammonium for-
mate, dimethyl sulfoxide (DMSO) were purchased
from Sigma-Aldrich (PoznaÒ, Poland). Erlotinib
(CAS number 183321-74-6) was purchased from
LGC Standards (£omianki, Poland). Water used in
the mobile phase was deionized, distilled and fil-
tered through a Millipore system before use. 
Drugs
Lapatinib ditosylate monohydrate, equivalent
to 250 mg lapatinib (TyverbÆ, 250 mg film-coated
tablets, batch number Y68Y) was purchased from
Novartis Polska Sp. z o.o., (Warsaw, Poland).
Clarithromycin (KlacidÆ 250 mg/5 mL, granules for
oral suspension, batch number 1072939) was pur-
chased from Abbott Laboratories Poland Sp. z o.o.
(Warsaw, Poland).
Animals
The experimental protocol for this study was
reviewed and approved by the Local Ethics
Committee (54/2017). All procedures were per-
formed in accordance with European Union regula-
tions concerning the handling and use of laboratory
animals. In order to obtain consistent data, the study
was based on the required minimum number of ani-
mals and observation time. The laboratory animals
included in the study came from Poznan University
of Medical Sciences breeding, from the Department
of Toxicology on Pharmaceutical Department. Adult
male Wistar-strain rats (weight 400-495 g) were 
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used in the study. The animals were maintained
under standard breeding conditions with a 12 h light
ñ 12 h dark cycle (lights on at 06.00, lights off at
18.00) at constant room temperature (23 ± 2OC), rel-
ative humidity (55% ± 10%) and given ad libitum
access to food and water. The animals were allowed
to acclimatize for a week before beginning the
experiment. After acclimatization, the rats were ran-
domly divided into two groups. One group (n = 6)
received first clarithromycin and next lapatinib
(ILap+Clar), second group (n = 6) received placebo
(0.9% NaCl) and lapatinib (IILap). Clarithromycin
was administrated at a dose of 25 mg per kg of body
weight to the ILap+Clar group (19, 20). Lapatinib (100
mg/kg) was dissolved in 1 mL DMSO (dimethyl sul-
foxide) and administered directly into the animal
stomach using a gastric probe. In order to make sure
that the animals received the entire dose of the drug,
1 mL of DMSO was then administered to rinse the
probe. 80 µL of blood was collected from each rat by
cutting off a piece of his tail. The blood samples for
lapatinib analysis were collected at the following
time points: 0, 15, 30 min, 1, 1.5, 2, 3, 4, 6, 8, 10, 24
and 30 h (per animal). The blood samples were
transferred into heparinized tubes and they were
centrifuged at 2880 x g for 10 min at 4OC. 
LC-MS/MS assay 
Lapatinib in plasma samples was determined
by means of a high performance liquid chromato-
graph (HPLC) Agilent 1200 Series (Agilent
Technologies, Waldbronn, Germany) coupled with
an Agilent 6410B triple quadrupole tandem mass
spectrometer (Agilent Technologies, Santa Clara,
CA, USA), which was a modification of the method
developed by Gˆtze L. et al. (27). HPLC separation
was carried out at 35OC in a Poroshell 120 EC C18
column (70 ◊ 3.0 mm, 2.7 µm, Agilent Technolo-
gies, USA). The mobile phase consisted of eluent A
(0.1% formic acid in water) and eluent B (0.1%
formic acid in acetonitrile). The flow rate was set at
500 µL/min and the gradient profile was as follows:
0-2 min, 5% B; 2-4 min, linear from 5% to 95% B;
4-5 min, 95% B; 5-6 min linear from 95% to 5% B;
6-10 min, 5% B. The multiple reaction monitoring
mode with two transitions for lapatinib and erlotinib
(internal standard, IS) was used. Lapatinib was mon-
itored at m/z 581.1→365.1 and 581.1→350.1,
whereas erlotinib at m/z 394.1→278.1 and
394.1→101.1. An aliquot of rat plasma (20 µL) was
added to 980 µL of methanol containing 5 ng of
erlotinib as internal standard and vortexed rigorous-
ly, for 30 seconds (total dilution factor 50). After
centrifugation, at 10,000 g (10 min), the supernatant
was transferred into amber glass HPLC vial and
injected (10 µL) onto the HPLC column. The
method was validated according to the European
Medicines Agency (EMA) guidelines on bioanalyti-
cal method validation (28). During the validation
four concentration levels of QC (quality control)
samples were analyzed (0.25; 0.5; 2500; 4000 µg/L). 
Evaluation of pharmacokinetics
The pharmacokinetic parameters were estimat-
ed with non-compartmental method, using software
PhoenixÆ WinNonlinÆ 8.1(Certara L.P.). The non-
compartmental approach was used for calculations
(NCA analysis method). AUC0-t ñ area under the
plasma concentration-time curve from zero to the
time of the last measurable concentration was calcu-
lated using linear trapezoidal rule described by
equation: AUC0-t =[(Cn + Cn + 1)/2] × ∆t, were Cn and
Cn+1 represents concentration points and related time
span (∆t); AUC0-∞ ñ area under the plasma concen-
tration-time curve from zero to infinity was calcu-
lated using linear trapezoidal rule described by
equation: AUC0-inf =[(Cn + Cn + 1)/2] × ∆t + Clast/kel)
were Clast is last measurable concentration; t1/2kel ñ
elimination half-life was calculated using equation:
t1/2kel = ln(2)/kel ; kel ñ elimination rate constant was
determined from the slope of log-transformed raw
data by a linear equation, curve fitting was per-
formed using the method of least squares; Cl/F ñ
clearance was calculated using equation: CL =
D/AUC0-inf where D represents dose value; Vd/F ñ
volume of distribution was calculated using equa-
tion: Vd/F = (D × AUMC0-inf)/AUC20-inf; Cmax ñ maxi-
mum plasma concentration was observed value; tmax
ñ time necessary to reach the maximum concentra-
tion was observed value; MRT0-t ñ mean residence
time based on data between zero and the time for the
last observed concentration was calculated from
equation: MRT0-t = AUMC0-t/AUC0-t; AUMC0-t ñ
area under the first moment curve from zero to the
time of the last measurable concentration was calcu-
lated using linear trapezoidal rule with equation:
AUMC0-t = [(tn × Cn + tn+1 × Cn+1)/2] × ∆t; AUMC0-∞
ñ area under the first moment curve from zero to
infinity was calculated using linear trapezoidal rule
with equation:  AUMC0-inf = [(tn × Cn + tn+1 × Cn+1)/2]
× ∆t + Clast/kel) (29).
Statistical analysis
The traits were tested for departure from nor-
mality using the Shapiro-Wilk test. The traits
which did not show significant deviation from nor-
mality were subject to the heterogeneity of varian-
ce test, followed by pooled (heterogeneity of
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variance test p-value > 0.05) or Satterthwaite (het-
erogeneity of the variance test p-value < 0.05) 
t-tests to verify the significance of differences
between the ILap+Clar and IILap. Differences between
the ILap+Clar and IILap in the characteristics which
showed significant deviation from normality were
tested with the Kruskal-Wallis test. The analysis
was performed using capability, t-test and npar 
1-way procedures of SAS (SAS Institute Inc. 2002-
2012. The SAS System for Windows version 9.4.
Cary, NC, USA). The 90% confidence intervals for
the ratio of geometric means were constructed,
except for tmax for which the confidence intervals
were based on the difference of medians. For tmax
non-parametric Kruskal-Wallis test was used to
evaluate significance of the difference between the
groups.
RESULTS
The analytical method was validated according
to the guidelines of the European Medicines Agency
(EMA) concerning bioanalytical method validation.
According to the guidelines, the internal standard
may be a structurally similar analog or a stable iso-
tope-labeled compound. The Authors chose
erlotinib because it belongs to the same group of
drugs as lapatinib (structurally similar analog).
Selected IS enabled good precision (coefficient of
variation, CV < 15%) and accuracy (%bias = 13%).
The calibration curves ranged within 0.25-5000
µg/L with the correlation coefficient r > 0.995. The
lower limit of quantification (LLOQ) was 0.25 µg/L.
During the sample preparation procedure, the dilu-
tion factor (DF = 50) was applied to quality control
Table 1. Plasma pharmacokinetic parameters for lapatinib following a single oral dose of lapatinib 100 mg/kg.
Gmean ratiob
Pharmacokinetic ILap+Clar IILap (90% CI)
parametersa (n = 6) (n = 6) ILap+Clar
vs. IILap
AUC0-t (µg ◊ h/L)
15627 ± 6066 13866 ± 6810 1.16
(38.8) (49.1) (0.75; 1.79)  
AUC0-∞ (µg ◊ h/L) 
18095 ± 9394 14540 ± 6495 1.21
(51.2) (44.7) (0.76; 1.94)  
kel (h-1) 
0.085 ± 0.046 0.136 ± 0.055 0.63
(53.8) (40.2) (0.36; 1.08)  
t1/2kel (h)
9.87 ± 4.26 6.66 ± 4.99 1.60
(43.1) (75.0) (0.93; 2.75)  
Cl/F (L/g ◊ h) 
0.009 ± 0.004 0.009 ± 0.003 0.98
(41.3) (39.5) (0.63; 1.54)  
Vd/F (L/g)
0.057 ± 0.009 0.060 ± 0.031 1.06
(16.1) (51.6) (0.65; 1.74)  
Cmax (µg/L)
2029.17 ± 276.30 1484.63 ± 324.49 1.38
(13.6) (21.9) (1.14; 1.68)  
tmaxc (h) 
2.5 < 2-4 > 2.0 < 1.5-2.0 > 0.5
(31.7) (27.4) (-0.45; 1.45)  
MRT0-t (h) 
7.29 ± 2.04 6.50 ± 1.54 1.11
(28.0) (23.7) (-0.45; 1.44)  
AUMC0-t (µg ◊ h2/L) 
123749 ± 83223 85662 ± 32144 1.28
(67.3) (37.5) (0.73; 2.25)
AUMC0-∞ (µg ◊ h2/L) 
249115 ± 279092 118078 ± 65165 1.57
(112.0) (55.2) (0.69; 3.59) 
kel ñ elimination rate constant; AUC0-t ñ area under the plasma concentration-time curve from zero to the time of the last measurable con-
centration; AUC0-∞ ñ area under the plasma concentration-time curve from zero to infinity; t1/2kel ñ elimination half-life; Cl/F ñ clearance;
Vd/F ñ volume of distribution; Cmax ñ maximum plasma concentration; tmax ñ time necessary to reach the maximum concentration; MRT0-t
ñ mean residence time; AUMC0-t ñ area under the first moment curve from zero to the time of the last measurable concentration; AUMC0-
∞ ñ area under the first moment curve from zero to infinity; a ñ arithmetic means ± standard deviations (CV%) are shown with CV (%) in
brackets; b ñ ratio of geometric means (Gmean) between groups (%) with the upper and lower bounds of a 90% confidence interval (CI) in
the brackets; except for tmax, where median differences are presented; c ñ these values are expressed as median < range >
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samples and plasma samples. As a result, the con-
centrations of the compound were 50 times lower
than those in undiluted rat plasma. In 2 samples after
30 h, the levels of lapatinib in the control group were
below the LLOQ. Matrix factor (MF) was used as a
quantitative measure to determine the matrix effect.
The variability of the IS-normalized MF from six
lots of matrix, measured by coefficient of variation
(CV%), in our method was less than 15%.
All the data were expressed as the mean value
± standard deviation (SD). The groups of rats did not
differ significantly in terms of body mass. The arith-
metic mean plasma concentrations of lapatinib after
its administration to the groups are shown in Figure
1. The figure does not represent a model fit but visu-
alization of raw data flow. The main pharmacoki-
netic parameters from non-compartmental methods
are summarized in Table I. Clarithromycin signifi-
cantly increased lapatinib Cmax by 36% (p = 0.0107).
When lapatinib and clarithromycin were coadminis-
tered, the AUC0-8 increased from 14540.25 to
18095.03 µg ◊ h/mL, but there was no statistical sig-
nificance (p = 0.4634). In the group of rats receiving
clarithromycin and lapatinib, t1/2kel was longer when
compared to the group receiving lapatinib, but there
was no statistical significance (p = 0.1093). No sta-
tistically significant differences were revealed for
area under the plasma concentration-time curve
from zero to the time of the last measurable concen-
tration (p = 0.6464), area under the plasma concen-
tration-time curve from zero to infinity (p = 0.4634),
clearance (p = 0.8722), volume of distribution (p =
0.8008), elimination rate constant (p = 0.1103),
elimination half-life (p = 0.1093), mean residence
time (p = 0.4678), area under the first moment curve
(p = 0.5218), area under the first moment curve from
zero to infinity (p = 0.3367).
DISCUSSION
The CYP3A4 isoenzyme participates in the
biotransformation of various drugs, which may
additionally exhibit inductive or inhibitory effect on
the activity of this isoenzyme. Phenytoin, carba-
mazepine, and rifampicin are well-known enzyme
inducers, whereas erythromycin, clarithromycin,
fluconazole, ketoconazole, and indinavir are enzyme
inhibitors (30). The experiments on rats showed that
clarithromycin may affect the pharmacokinetics of
lapatinib. It is a first study describing in vivo inter-
action between lapatinib, new tyrosine inhibitor and
the broadly used macrolide antibiotic. A single
administration of clarithromycin and lapatinib
resulted in the extension of tmax (2.83 vs. 2.00 h) for
tyrosine kinase inhibitor and a significant increase in
the mean Cmax, as compared with the group which
received lapatinib only (2029.17 vs. 1484.63 µg/L).
It is likely that the changes were caused by the
inhibitory effect of clarithromycin on P-gp and
CYP3A4. In consequence, the drug absorption
increased, whereas lapatinib metabolism decreased.
Moreover, Aueviriyavit et al. revealed that clar-
ithromycin exhibited markedly weaker mechanism-
based inactivation effects on CYP3A activity in rat
liver microsomes compared to human liver micro-
somes, therefore the effect in our study can be
Figure 1. Lapatinib plasma concentrationñtime profiles in rats receiving lapatinib + clarithromycin (ILap+Clar) and lapatinib (IILap)
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enhanced in humans (31). Apart from that, due to
the fact that lapatinib is an inhibitor of P-gp, where
clarithromycin is the substrate, the concentration of
the antibiotic in the blood may increase. In conse-
quence, its pharmacological effect and interaction
potential will increase. Moreover, the effect of
DMSO on lapatinib pharmacokinetics can not be
excluded, especially for drug metabolism. DMSO is
a cheap and broadly used solvent and carrier for
many drugs. In the experiment, lapatinib was dis-
solved in 1 mL DMSO and administered directly
into the animal stomach. DMSO may inhibit
CYP1A2, 2C8/9, 2 C19, 2D6, 2E1 and CYP3A4 in
various degree (32), but DMSO did not alter plasma
creatinine concentrations in rat and in small doses
did not have influence on oral drug absorption (33,
34). Because all rats received the same amount of
the solvent, observed differences in lapatinib con-
centrations between analyzed two groups of animals
were not caused by DMSO. 
The clinical significance of the potential
increase in the Cmax of lapatinib, when administered to
patients in combination with CYP3A4 inhibitors, has
not been clearly defined yet. The similar experiment
which concerned potential interaction between antibio-
tic and tyrosine kinase inhibitor proved that antibio-
tics like ciprofloxacin (fluoroquinolone) can lead to
increased concentrations of sunitinib in the cere-
brospinal fluid in rabbits. Probably reason of that is
inhibition CYP3A4 by the ciprofloxacin (35). Like
other tyrosine kinase inhibitors, lapatinib is a drug
with a wide therapeutic range. Investigations have not
revealed a relationship between lapatinib plasma con-
centrations and the occurrence of side effects (SE).
The most common SE of lapatinib is diarrhea, which
causes dehydration and was observed in nearly half of
the patients treated with the drug. The occurrence of
such symptoms as: moderate to severe diarrhea,
severe nausea or vomiting, and severe cramping, sig-
nificantly reduces the patientís quality of life and
causes the need to stop taking the drug until recovery
and then reduce its dose (36). However, it is known
that the development of diarrhea is related to the oral
dose rather than the drug plasma concentration (37).
The relation between lapatinib concentration and
hepatotoxicity may be different. It is a frequent
adverse effect of this tyrosine kinase inhibitor, which
causes discontinuation of treatment. Liver damage is
the result of the inhibition of ABCB1 transporters by
lapatinib. It increases the toxicity of the compounds
which are substrates of ABCB1 transporters, such as
paclitaxel and doxorubicin (38). Due to the fact that
lapatinib is a substrate for the P-gp transport protein,
it cannot be ruled out that a higher concentration of
the drug combined with clarithromycin, which is a
CYP3A4 and P-gp inhibitor, will not increase the
hepatotoxicity of the anticancer therapy (39).
Limitation of the study is single dose design. The in
vivo inhibitory effect caused by clarithromycin could
be more prominent after multiple dosing. Future
research directions include therapeutic drug monitor-
ing in patients who are treated with lapatinib and the
macrolide antibiotics (clarithromycin and erythromy-
cin) to confirm or exclude clinical significance of the
interaction. Additionally, because of increased risk of
hepatotoxicity after concomitant use of the tyrosine
kinase inhibitor and clarithromycin, monitoring of
liver function should be considered. 
CONCLUSION
Single oral administration of clarithromycin
significantly increased concentration of lapatinib in
rats, therefore caution should be taken during con-
comitant treatment with this macrolide and the tyro-
sine kinase inhibitor in patients.
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